German Accelerator Life Sciences (GALS) - Advise, Connect, Inspire

German Accelerator Life SciencesGerman Accelerator Life Sciences (GALS) helps young German life science companies succeed in the global market. GALS provides individualized and highly flexible services, tailored towards the specific needs and objectives of startups and emerging companies in the life sciences. Experienced mentors and consultants work with the participating teams to establish networks of potential clients, partners, and investors.

Applicants must be promising emerging life science companies that have great potential to benefit from the GALS program. Companies must have an affiliation with Germany, i.e. incorporated in Germany or with significant operations there. Applicants must develop a product or service in (at least) one of the five supported life science segments: Digital Health, Medical Devices, Diagnostics, Therapeutics, or Platform Technologies. The stage of the company's growth is relevant; the age of the company is not.

Application
The GALS application consists of around 20 questions about your company, team, technology, and business plan. It only takes a couple of hours to complete. We also request that companies submit additional materials with their application, such as a slide deck and a product demo (if available). Companies apply to the GALS program via the F6S platform.

GALS accepts companies into the program on a rolling basis. Companies can apply any time. Applications are reviewed by the Selection Committee every 6-8 weeks. Program start dates are flexible.

Next application deadline: March 31, 2017

The GALS Selection Committee meets approximately every 6-8 weeks to evaluate new applications. GALS then invites selected promising companies to an in-person workshop for a further assessment of their technology/approach and business strategy.

All services provided by GALS are free of charge for program participants, however GALS will not cover any related travel or living expenses.

For further infromation, please visit:
http://germanaccelerator.com/life-sciences/

About the German Accelerator Life Sciences
The German Accelerator Life Sciences (GALS) is an initiative of the German Federal Ministry for Economic Affairs and Energy (BMWi), with the goal of helping German startups and young companies succeed in the global marketplace. GALS offers support in multiple areas, from free office space in the world's leading life science innovation hub, to mentoring and advising from industry experts and experienced leaders. GALS opened its doors in October 2015 and has its headquarters in Cambridge, Massachusetts.

Most Popular Now

NHS Staff Punished as 500,000 Rely on Wh…

WhatsApp, Facebook Messenger and other unauthorised instant messaging (IM) apps are being used by approximately 500,000 NHS staff at work, as a growing number turn to consumer tools to communicate...

Call for Abstracts: European Telemedicin…

27 - 29 May 2018, Sitges, Barcelona, Spain. The European Telemedicine Conference 2018 (ETC18) is an interdisciplinary forum for healthcare professionals, directors, managers, and researchers with the intent of bringing together...

conhIT 2018: The stage is Set for Dialog…

17 - 19 April 2018, Berlin, Germany. Finding out about and supporting all aspects of the digital transformation of the healthcare system: that is what this year's conhIT, Europe's largest event...

Smartphone 'Scores' can Help Doctors Tra…

Parkinson's disease, a progressive brain disorder, is often tough to treat effectively because symptoms, such as tremors and walking difficulties, can vary dramatically over a period of days, or even...

Portable Device Detects Severe Stroke in…

A new device worn like a visor can detect emergent large-vessel occlusion in patients with suspected stroke with 92 percent accuracy, report clinical investigators at the Medical University of South...

Focus on the Digital Transformation - A …

17 - 19 April 2018, Berlin, Germany. How is the digitalisation of the healthcare system affecting the relationship between patients and doctors? What new innovations and solutions does the health IT...

Imitation is the Most Sincere Form of Fl…

For every two mobile apps released, one is a clone of an existing app. However, new research published in the INFORMS journal Information Systems Research shows the success of the...

Blackpool Teaching Hospitals Triggers Di…

Blackpool Teaching Hospitals NHS Foundation Trust has laid the foundations for an ambitious digitisation programme, by deploying IMS MAXIMS technology in its emergency department. The go-live is already helping staff...

Merck Partners with Medisafe to Help Imp…

Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication intake and adhere to prescribed treatment regimens...

Philips Research-led Big Data Consortium…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, together with its consortium partners, today announced that it has received funding from the EU's Horizon 2020 program...

Smartphone App Performs Better than Trad…

A smartphone application using the phone's camera function performed better than traditional physical examination to assess blood flow in a wrist artery for patients undergoing coronary angiography, according to a...